Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation

Blood

Volumn 97, Issue 1, 2001, Pages 101-106

  Colombat, Philippe ^b   Salles, Gilles ^b   Brousse, Nicole ^b   Eftekhari, Pitahey ^b   Soubeyran, Piere ^b   Delwail, Vincent ^b   Deconinck, Eric ^b   Haïoun, Corinne ^b   Foussard, Charles ^b   Sebban, Catherine ^b   Stamatoullas, Astasia ^b   Milpied, Noël ^b   Boué, François ^b   Taillan, Bruno ^b   Lederlin, Pierre ^b   Najman, Albert ^b   Thièblemont, Catherine ^b   Montestruc, François ^b   Mathieu Boué, Anne ^b   Benzohra, Aziz ^b   Solal Céligny, Philippe ^a   more..

^a CENTRE JEAN BERNARD   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; MONOCLONAL ANTIBODY; PARACETAMOL; PROTEIN BCL 2; RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0035169514     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.1.101     Document Type: Article

References (36)

1. Treatment approaches to the low-grade lymphomas
2. The treatment of indolent lymphomas: Watchful waiting versus aggressive combined modality treatment
3. Comparison in low-tumor burden follicular lymphomas between an initial no-treatment policy, prednimustine or interferon alpha: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires
4. Treatment of B-cell lymphomas with anti-idiotype antibodies alone or in combination with alpha interferon
5. Monoclonal anti-idiotype antibody therapy of B-cell-lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells
6. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
7. A phase I study an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B cell lymphomas resistant to conventional therapy
8. Phase I trial of an anti-CD19-deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: Effect of an intensive schedule of administration
9. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B cell lymphoma
10. Iodine-131 anti-B1 radioimmunotherapy for B cell lymphoma
11. Yttrium-90 labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
12. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
13. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem cell rescue
14. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20
15. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
16. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
17. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
18. Feasibitity and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-CDB8, rituximab) in relapsed B cell lymphoma
19. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
20. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
21. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance
22. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
23. Phase II study of rituximab (Rituxan) in patients with previously untreated low-grade or follicular non-Hodgkin's lymphoma
24. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
25. Genetic polymorphisms in the tumor necrosis factor region and non-Hodgkin's lymphoma outcome
26. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma
27. Nonparametric estimation from incomplete observations
28. Rituxan (rituximab, IDEC-C2B8): Interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma
29. Retreatments with Rituxan (rituximab, IDEC-C2B8) have significant efficacy, do not cause harm, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL)
30. PCR analysis for the t(14;18) translocations in patients with recurrent follicular lymphoma following immunotherapy with rituximab (IDEC-C2B8)
31. The clinical significance of molecular response in indolent follicular lymphomas
32. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow
33. Persistence of circulating t(14;18) cells in long-term remission after radiation therapy for localized stage follicular lymphomas
34. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
35. Phase I/II clinical trial to evaluate the safety and efficacy of a combination of a chimeric anti-CD20 monoclonal antibody (rituximab) and G-CSF given weekly to patients with relapsed B cell lymphoma
36. Combination immunotherapy of low-grade or follicular non-Hodgkin's lymphoma with rituximab and alpha interferon: Interim analysis